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ABSTRACT
Gestational Diabetes Mellitus (GDM) is a metabolic disorder that is considered a prediabetes state. According to the In-
ternational Diabetes Federation every year an increase in the number of women diagnosed with gestational diabetes is 
being noticed. It is known that GDM can cause many complications during pregnancy and labor. What is more, women 
with GDM history and their offspring are at risk of developing diabetes in the future. A new factor in the pathogenesis 
of GDM is epigenetics, which is described as changes in gene expression without directly modifying the DNA sequence. 
One of its regulating mechanisms is based on microRNA (miRNA). A small non-coding RNA sequence that has an influence 
on protein formation by suppressing gene expression. A better understanding of the miRNA’s function could potentially 
lead to their usage as potential new biomarkers or treatment targets. In this article we review the most significant miRNA 
molecules in gestational diabetes.  
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INTRODUCTION
Gestational Diabetes Mellitus
Gestational Diabetes Mellitus (GDM) is a metabolic dis-
order which is characterized by carbohydrate intolerance 
first recognized during pregnancy. Despite many years of 
experimental studies, the pathogenesis of GDM remains 
unclear. Increased insulin secretion and progressive insulin 
resistance are physiological phenomena during pregnancy. 
This occurs due to adipose tissue growth and elevated lev-
els of insulin antagonists such as progesterone, estrogen, 
prolactin and placental lactogen [1]. Normally, there is 
an increase of insulin secretion by the pancreatic β-cells 
to sustain normoglycemia. However, in GDM insufficient 
insulin compensation is being observed [1, 2]. Risk factors 
of developing GDM include previous GDM history, maternal 
obesity or overweight, older age, family history of diabetes 
mellitus, previous child macrosomia, fetal death or stillbirth 
history. Currently, an increase in the incidence of GDM is 
being noted, especially in developed countries. The Inter-
national Diabetes Federation estimated that almost one in 
six births are affected by GDM [3, 4].
More than 40 years ago, O’Sullivan JB created the first 
diagnostic criteria [5] that have been improved over the 
years. Currently, GDM diagnosis is based on Oral Glucose 
Tolerance Test (OGTT) with 75 g of glucose dissolved in 
300ml of water measured between the 24th and the 
28th week of pregnancy. The implementation of these crite-
ria by World Health Organization (WHO) and International 
Association of the Diabetes and Pregnancy Study Groups 
(IADPSG) was based on the Hyperglycemia and Adverse 
Pregnancy Outcome (HAPO) study [6] (Tab. 1).
Epigenetics
Epigenetics is a rapidly growing field of science. 
The term includes any changes in the gene activity without 
modification in the DNA sequence. It was used for the first 
Table 1. Cut-off values for diagnosing gestational diabetes 
mellitus according to International Association of the Diabetes 
and Pregnancy Study Groups [6]
International Association of Diabetes and Pregnancy Study Group
Fasting glucose [mmol/L] ≥ 5.1
1-hour glucose [mmol/L] ≥ 10
2-hour glucose [mmol/L] ≥ 8.5
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time in 1939 in Waddington’s paper [7]. For many years 
now, scientists have been interested in the mechanism of 
epigenetics and have studied this phenomenon extensively. 
Furthermore, the development of diagnostic techniques 
will allow for a more accurate analysis of changes that are 
not related with changes in the gene sequence. Epigenetic 
mechanisms operate through the regulation of gene expres-
sion as a result of chemical modification of DNA or proteins 
related to DNA. Thus far, the best known of the mentioned 
processes are DNA methylation, histone alteration, chro-
matin modification and a mechanism that uses non-coding 
RNA sequences (microRNA) [8]. This article will concentrate 
on the role of microRNA (miRNA) as an epigenetic mecha-
nism in GDM development.
MicroRNA
MiRNA was discovered in 1993 by Rosalind C. Lee, Rhon-
da L. Feinbaum and Victor Ambros [9] and from that time 
the state of  knowledge has significantly expanded. MiRNA 
expression occurs in several stages. 
The first pathway starts with the DNA transcription 
catalyzed by RNA polymerase II and III which then forms 
harpin structure primary-miRNA (pri-miRNA). The pri-miRNA 
is processed in the nucleus by the RNase III Drosha en-
zyme into the pre-miRNA. Subsequently, it continues in 
the cytoplasm with the use of the Dicer enzyme resulting 
in 19–22 double-stranded miRNA nucleotides. In the next 
stage the RNA-induced silencing complex (RISC) is being 
formed. One of the strands degrades and the second takes 
part in gene transcription regulation. 
There is a second pathway — The Mirtron Pathway of 
miRNA formation. During the splicing process the pri-miRNA 
is being created and then it follows the same pattern as 
stated above [10].
For many years it was considered that non-coding se-
quences of RNA had no significant role. Whereas nowadays 
it have been proved that that one mRNA may contain many 
binding locations for different miRNAs and that one miRNA 
can affect several different genes [10, 11]. The RISC-miRNA 
complex can interact with the target mRNA, without perfect 
homology and consequently, inhibit the translation process 
or lead to the degradation of complementary RNA [12]. 
The main role of microRNA is the regulation of post-tran-
scriptional gene expression through the mechanisms of 
mRNA cleavage or deadenylation, leading to the down-reg-
ulation of gene expression by [13]. On the other hand, 
miRNA can possibly promote protein expression. MiRNA 
can play a role in enhancing the organism’s response to 
stress and can have an impact on many pathological pro-
cesses [14]. Furthermore, it is known that miRNA can play 
a role in autocrine or paracrine regulations and it is present 
in every kind of human fluid.  
MIRNAS IN GESTATIONAL 
DIABETES MELLITUS
One of the first papers assuming the usefulness of a miR-
NAs in diagnosis of GDM was Zhao C. et al. [15] article. They 
suggest three miRNAs as an early serum biomarker of GDM, 
hsa-miR29a, hsa-miR222 and has-miR132 whose level was 
significantly decreased in GDM compared to the control 
group. Hsa-miR29a is known as a regulating factor for he-
patic gluconeogenesis and a stimulator for insulin secretion 
by the pancreatic β cells contributing to preventing diabetes 
development [15, 16]. Meta-analysis conducted by Zhu H. 
[17] has confirmed the presence of miR-29a and miR-132 in 
the blood of T2 diabetes patients, whereas upregulation of 
miR-222 has been noted in the adipose tissue of GDM pa-
tients. It is known that estrogen receptor α (Erα) is a target 
for miR-222, which, when activated, leads to an increase in 
estrogen concentration and consequently, the inhibition 
of GLUT4 transporter. That phenomenon leads to estrogen 
induced insulin resistance [18].
Zhu Y. et al. [19], reported a potential biomarker role of 
miR-16-5p, miR-17-5p, miR-19a-3p, miR-19b-3p and 20a-5p 
which were upregulated in the plasma taken from the GDM 
patients between 16–19th weeks of pregnancy. Cao L.Y. et al. 
[20], checked those miRNAs in plasma samples of women 
between 24th–28th weeks of pregnancy when GDM is usually 
diagnosed. Results confirmed a significant upregulation of 
miR-16-5p, miR-17-5p and 20a-5p. Moreover, authors proved 
a  positive correlation of those miRNAs and HOMA-IR, one of 
the indicators of GDM. Data describes the role of miR-16-5p 
and miR-17-5p in pathogenesis of T2 diabetes. Target genes 
for miR-16-5p were reported as downregulated genes in 
T2 diabetes. The miR-17-5p is involved in cell proliferation and 
is upregulated especially in samples from diabetic patients 
with vascular complications. So far, there is no data about 
the role of miR-20a-5p in diabetes development [19, 20]. 
Surprisingly, Carmen Pheiffer [21] did not show an increased 
expression of miR-16-5p and 17-5p in his paper. Only miR-
20a-5p was upregulated. The difference between those 
results may be caused by race because Zhu and Cao [19] 
examined Asian women, whereas Carmen conducted his 
research in South Africa. MiRNA occurrence is sensitive and 
can depend on many factors such as BMI, race, nutrition and 
even sex of the fetus.
More recently, Sebastiani G. et al. [22], reported a miR-330 
upregulation in GDM plasma. They found a correlation be-
tween miR-330 level and caesarean section rate and preg-
nancy complications (fetal macrosomia, polyhydramnios 
and maternal hydronephrosis). Authors suggested that 
high levels of examined miRNA may predispose to a more 
severe diabetic phenotype. Proof of miR-330 involvment 
in GDM pathophysiology are the target genes, CDC42 and 
E2F1. Both are associated with insulin resistance. CDC42 im-
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paired insulin release whereas E2F1 reduced beta-cells pro-
liferation [23, 24].
During pregnancy, an additional source of miRNA is the 
placenta. Nair S. at al. [25], reported that has-miR-125a-3p 
and has-miR224-5p were upregulated in chorionic villi and 
skeletal muscle tissue in GDM. Those RNAs are involved in 
CD40 and Glypican 4 expression which are associated with 
body fat composition and insulin resistance (correlation with 
HOMA-IR). What is more, a glypican 4 has an affinity to insulin 
receptors and increases insulin signaling [26]. Increased 
miR-125a-3p level was also described in the liver and the 
adipose tissue in a diabetic rat model as a molecule involved 
in insulin resistance development. The target for miR-125a-
3p is PI3K, a crucial kinase in PI3K/AKT pathway leading to 
an increased glucose uptake in skeletal muscle [27].
Human Molecular Genetics published a paper indi-
cating long term effects in the adult offspring of women 
with GDM. Individuals exposed to maternal diabetes have 
an increased miR-15a and miR-15b expression in skeletal 
muscle. These miRNAs may alter the expression of proteins 
important in insulin signaling pathways and decrease insu-
lin receptors development causing impaired glucose toler-
ance or even diabetes in the offspring of diabetic women 
[28]. It testifies that epigenetics could potentially prove 
a potent diagnostic tool and a treatment option being 
a chance for a better care for people suffering from GDM 
and its complications.
SUMMARY
Due to the fact that miRNAs are resistant to RNase and 
remain stable in tissues and body fluids, even after multiple 
freeze-throw cycles, changes in their expression may be 
both sensitive and specific indicators of metabolic disorders 
like gestational diabetes mellitus (GDM). Furthermore, miR-
NAs can be collected from peripheral blood, thus rendering 
miRNAs an easy to collect, minimally invasive diagnostic 
biomarker [17]. However, changes in the miRNA expression 
in the blood during hyperglycemia complicated pregnancy 
have so far been ambiguous and further research needs to 
be done to create a GDM prediction miRNA profile.
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